Navigation Links
Liraglutide provides significantly better glucose control than,insulin glargine in phase 3 study

COPENHAGEN, June 21, 2007-Novo Nordisk today announced clinical results from the first of five phase 3 studies with liraglutide - the once-daily human GLP-1 analogue. The 26-week study is part of the LEAD(TM) (Liraglutide Effect and Action in Diabetes) programme and included 581 patients with type 2 diabetes inadequately controlled by two of the most widely used oral antidiabetic drugs: metformin and a sulfonylurea (glimepiride). All patients in the study continued the two oral drugs and were randomised to add one daily injection of liraglutide, placebo or insulin glargine.

The average HbA1c level at the beginning of the study was between 8.0% and 8.5% and at the end of the study, more than 50% of patients in the liraglutide group had reached the American Diabetes Association goal of HbA1c < 7%. Furthermore, more than 35% achieved the American Association of Clinical Endocrinologists HbA1c target of <= 6.5%. The HbA1c reduction achieved in the liraglutide group was more than 0.2 percentage points better than in the insulin glargine group, a difference which is statistically significant.

The average weight of the patients at the beginning of the study was approximately 85 kg. At the end of the study, the difference in body weight between the liraglutide and insulin glargine treatment groups was on average 3.5 kg, statistically significant in favour of liraglutide.

Liraglutide in combination with metformin and glimepiride was well tolerated. The most frequently reported adverse event in the liraglutide arm was nausea at an absolute level of between 10 and 15%. As expected, the combination of a GLP-1 analogue with a sulfonylurea leads to some of the patients experiencing hypoglycaemia. The overall hypoglycaemia event rate in the liraglutide and insulin glargine groups was not significantly different.

Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk, said: "We are very
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
2. Positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy
3. Placebo-controlled Phase IIa Study with the Immunotherapeutic CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in Hay Fever Patients
4. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
5. Isotechnikas independent data monitoring committee conducts review of phase 2b kidney transplant trial
6. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
7. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
8. 2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion
Post Your Comments:
(Date:9/16/2014)... 2014  DNAtrix, Inc., experts in oncolytic virus ... treated with the company,s lead product, DNX-2401, a ... randomized, multicenter, open-label Phase Ib study for patients ... with leading neurosurgeons and neuro-oncologists in the US, ... randomized Phase Ib study of DNX-2401 at Moffitt ...
(Date:9/16/2014)... 16, 2014  Eli Lilly and Company (NYSE: ... an agreement to co-develop and commercialize AZD3293, an ... in development as a potential treatment for Alzheimer,s ... is characterized by the accumulation of amyloid plaque ... with the development of beta-amyloid. Inhibiting BACE is ...
(Date:9/15/2014)... Sept. 16, 2014  Bayer HealthCare and Orion ... Finland , have begun to enroll ... an investigational oral androgen receptor inhibitor in clinical ... men with castration-resistant prostate cancer who have rising ... metastases. The trial is designed to determine the ...
Breaking Medicine Technology:DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 2Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 2Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 3Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 4Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 2Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 3
... Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced that ... at the Lazard Capital Markets 8th Annual Healthcare Conference, being ... Bentsur,s presentation is scheduled to take place on Wednesday, November ... audio webcast of Mr. Bentsur,s presentation will be accessible from ...
... 2011 Booth # 407 at The American ... NxStage® Medical, Inc. (Nasdaq: NXTM ), ... announced that its Medisystems division has won a ... Solution to Atlantic Dialysis Management Services centers. ...
Cached Medicine Technology:Keryx Biopharmaceuticals to Present at Lazard Capital Markets 8th Annual Healthcare Conference 2NxStage Awarded Multi-Year Contract to Supply Atlantic Dialysis Management Services with Vasc-Alert Access Surveillance Solution 2NxStage Awarded Multi-Year Contract to Supply Atlantic Dialysis Management Services with Vasc-Alert Access Surveillance Solution 3
(Date:9/16/2014)... NEW YORK, NY (September 16, 2014) The ... received the 2014 Higher Education Excellence in Diversity ... oldest and largest diversity-focused publication in higher education. ... national honor recognizing U.S. colleges and universities that ... will be featured along with 82 other recipients ...
(Date:9/16/2014)... Orange, NJ. September 16, 2014. Kessler Foundation researchers ... slowed processing speed in the executive deficits found ... slowed processing speed account for executive deficits in ... neuroimaging," was published online ahead of print on ... The authors are Victoria Leavitt, PhD, of ...
(Date:9/16/2014)... judges are the unwitting focus of some of Australia,s ... to improve their performance in competition, thanks to a ... Dr Daniel Greenwood, from QUT,s Institute of Health and ... Sport Centre of Excellence for Applied Sport Science Research, ... such as cricket, long jump, triple jump and pole ...
(Date:9/16/2014)... San Francisco, September 15, 2014 For patients with ... and stereotactic ablative radiation (SABR) may be a ... surgery that may not otherwise be an option, ... Society for Radiation Oncology,s (ASTRO,s) 56th Annual Meeting. ... for individuals with pancreatic ductal adenocarcinoma (PDA), the ...
(Date:9/16/2014)... be presented at the ESMO 2014 Congress will be ... (CEST) to give you a first glimpse of what ... under the leading theme Precision Medicine in Cancer Care. ... therapy is now possible for an increasing number of ... towards a common goal --improved patient outcomes. This is ...
Breaking Medicine News(10 mins):Health News:Columbia University College of Dental Medicine receives diversity award 2Health News:Columbia University College of Dental Medicine receives diversity award 3Health News:Columbia University College of Dental Medicine receives diversity award 4Health News:Getting the jump on competitors: QUT study 2Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 2Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 3Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 4Health News:ESMO 2014 Congress Preview 2
... School of Medicine has helped confirm the reliability of ... individual's genetic makeup. ,The Stanford group was ... the genetic test can identify patients who are at ... infection. That means high-risk patients could be directed toward ...
... A report released by the Australian Institute of Health ... in Queensland. Nearly 20 to 50% of the population ... to be relying on anti-depressants heavily. ... affair in Queensland where nearly 11,500 prescriptions for anti ...
... today has become the number one killer. More so, related ... occupational Hazard// with millions of people running the risk of ... fibers and second hand smoker are the major causes of ... from exposure to benzene from the dye, drugs, pesticides and ...
... the world. There is also a rise of alcohol abuse ... women says that in women cognitive problems develop faster in ... subject to physical changes in the brain more rapidly than ... at the research institute RTI at the university in Baltimore ...
... Institute of Medicine released a report recommending nutrition ... school environment, such as a la carte cafeteria ... Dairy Council (NDC) applauds the overall recommendations outlined ... nonfat and low-fat dairy products, fruits, vegetables and ...
... An international research team, led by investigators from the ... Institute (DFCI), has found// a new way that some ... drugs like Iressa and Tarceva. Their report, which will ... online release, describes a totally new resistance mechanism that ...
Cached Medicine News:Health News:New Test Helps Identify Hepatitis C Patients at High Risk of Developing Cirrhosis 2Health News:New Test Helps Identify Hepatitis C Patients at High Risk of Developing Cirrhosis 3Health News:Today Cancer is the Deadliest Killer 2Health News:Alcoholism Develops Cognitive Problems in Women 2Health News:National Academy of Sciences' Institute of Medicine Report Calls for More Dairy Foods at School 2Health News:New Mechanism Identified for Resistance to Targeted Lung Cancer Drugs 2Health News:New Mechanism Identified for Resistance to Targeted Lung Cancer Drugs 3
... Innovations' Instrument Manager (IM) is an instrument ... system that enables laboratories to work more ... as a data management solution that stands ... information system, filling those important gaps in ...
... These color vision tests have been designed ... the type and estimating the grade of ... measure Red, Green, Blue, Yellow. They provide ... deficiencies. Screening is accomplished using the initial ...
... sets are designed to indicate color deficiency ... is used to separate Medium and Strong ... test is much more difficult and is ... Both of these tests provide basic ...
Single Use Loading Units with Titanium Staplers for use with MULTIFIRE ENDO TA™ 30 12 mm (Single Use Staplers with Titanium Staplers)....
Medicine Products: